{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:28:26Z","timestamp":1740166106622,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s13760-024-02597-8","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T03:33:21Z","timestamp":1722656001000},"page":"1935-1944","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between peripheral blood immunological status and intrathecal inflammatory markers differentiate multiple sclerosis clinical phenotypes"],"prefix":"10.1007","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8138-4170","authenticated-orcid":false,"given":"Ana","family":"Tur\u010di\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josip","family":"Kne\u017eevi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ljiljana","family":"Zaninovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Habek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena Krbot","family":"Skori\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonija","family":"Babi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u017deljka","family":"Vogrinc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,3]]},"reference":[{"key":"2597_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"key":"2597_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ensci.2018.07.002","volume":"12","author":"A Dastagir","year":"2018","unstructured":"Dastagir A, Healy BC, Chua AS et al (2018) Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis. eNeurologicalSci 12:42\u201346. https:\/\/doi.org\/10.1016\/j.ensci.2018.07.002","journal-title":"eNeurologicalSci"},{"key":"2597_CR3","doi-asserted-by":"publisher","first-page":"854390","DOI":"10.3389\/fneur.2022.854390","volume":"13","author":"N Manouchehri","year":"2022","unstructured":"Manouchehri N, Salinas VH, Rabi Yeganeh N et al (2022) Efficacy of Disease Modifying therapies in Progressive MS and how Immune Senescence may explain their failure. Front Neurol 13:854390. https:\/\/doi.org\/10.3389\/fneur.2022.854390","journal-title":"Front Neurol"},{"key":"2597_CR4","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3389\/fimmu.2020.00760","volume":"11","author":"J van Langelaar","year":"2020","unstructured":"van Langelaar J, Rijvers L, Smolders J, van Luijn MM (2020) B and T cells driving multiple sclerosis: identity, mechanisms and potential triggers. Front Immunol 11:760. https:\/\/doi.org\/10.3389\/fimmu.2020.00760","journal-title":"Front Immunol"},{"key":"2597_CR5","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","volume":"9","author":"H Lassmann","year":"2019","unstructured":"Lassmann H (2019) Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol 9:3116. https:\/\/doi.org\/10.3389\/fimmu.2018.03116","journal-title":"Front Immunol"},{"key":"2597_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3325\/cmj.2022.63.379","volume":"63","author":"M Habek","year":"2022","unstructured":"Habek M, Adamec I, Barun B et al (2022) Treatment of relapsing multiple sclerosis - recommendations of the Croatian neurological society. Croat Med J 63:379\u2013388. https:\/\/doi.org\/10.3325\/cmj.2022.63.379","journal-title":"Croat Med J"},{"key":"2597_CR7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ et al (2018) ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Scler J 24:96\u2013120. https:\/\/doi.org\/10.1177\/1352458517751049","journal-title":"Multiple Scler J"},{"key":"2597_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-510X(94)90298-4","volume":"122","author":"H Reiber","year":"1994","unstructured":"Reiber H (1994) Flow rate of cerebrospinal fluid (CSF) \u2014 a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J Neurol Sci 122:189\u2013203. https:\/\/doi.org\/10.1016\/0022-510X(94)90298-4","journal-title":"J Neurol Sci"},{"key":"2597_CR9","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/jnnp.57.8.897","volume":"57","author":"M Andersson","year":"1994","unstructured":"Andersson M, Alvarez-Cerme\u00f1o J, Bernardi G, Cogato I, Fredman P, Frederiksen J, Fredrikson S, Gallo P, Grimaldi LM, Gr\u00f8nning M et al (1994) Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 57:897\u2013902. https:\/\/doi.org\/10.1136\/jnnp.57.8.897","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2597_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/400_2009_9012","volume":"51","author":"C Severson","year":"2010","unstructured":"Severson C, Hafler DA (2010) T-Cells in multiple sclerosis. Results Probl Cell Differ 51:75\u201398. https:\/\/doi.org\/10.1007\/400_2009_9012","journal-title":"Results Probl Cell Differ"},{"key":"2597_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2022.996469","volume":"13","author":"R Liu","year":"2022","unstructured":"Liu R, Du S, Zhao L et al (2022) Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target. Front Immunol 13:1\u201323. https:\/\/doi.org\/10.3389\/fimmu.2022.996469","journal-title":"Front Immunol"},{"key":"2597_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.msard.2018.12.019","volume":"28","author":"YF Li","year":"2019","unstructured":"Li YF, Zhang SX, Ma XW et al (2019) The proportion of peripheral regulatory T cells in patients with multiple sclerosis: a meta-analysis. Mult Scler Relat Disord 28:75\u201380. https:\/\/doi.org\/10.1016\/j.msard.2018.12.019","journal-title":"Mult Scler Relat Disord"},{"key":"2597_CR13","doi-asserted-by":"publisher","first-page":"832","DOI":"10.4049\/jimmunol.1500759","volume":"195","author":"T Dhaeze","year":"2015","unstructured":"Dhaeze T, Peelen E, Hombrouck A et al (2015) Circulating Follicular Regulatory T Cells Are Defective in multiple sclerosis. J Immunol 195:832\u2013840. https:\/\/doi.org\/10.4049\/jimmunol.1500759","journal-title":"J Immunol"},{"key":"2597_CR14","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1177\/1352458518779951","volume":"25","author":"M Puthenparampil","year":"2018","unstructured":"Puthenparampil M, Zito A, Pantano G et al (2018) Peripheral imbalanced TFH\/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset. Multiple Scler J 25:918\u2013926. https:\/\/doi.org\/10.1177\/1352458518779951","journal-title":"Multiple Scler J"},{"key":"2597_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1146\/annurev-pathol-052920","volume":"17","author":"SR Mur\u00faa","year":"2021","unstructured":"Mur\u00faa SR, Farez MF, Quintana FJ (2021) The Immune response in multiple sclerosis. Annual Review of Pathology: mechanisms of Disease. Annu Rev Pathol Mech Dis 17:121\u2013139. https:\/\/doi.org\/10.1146\/annurev-pathol-052920","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"2597_CR16","doi-asserted-by":"publisher","first-page":"e693","DOI":"10.1212\/NXI.0000000000000693","volume":"7","author":"M Cellerino","year":"2020","unstructured":"Cellerino M, Ivaldi F, Pardini M et al (2020) Impact of treatment on cellular immunophenotype in MS: a cross-sectional study. Neurol Neuroimmunol Neuroinflamm 7:e693. https:\/\/doi.org\/10.1212\/NXI.0000000000000693","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2597_CR17","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3390\/cells12030439","volume":"12","author":"J Canto-Gomes","year":"2023","unstructured":"Canto-Gomes J, Da Silva-Ferreira S, Silva CS et al (2023) People with Primary Progressive multiple sclerosis have a Lower Number of Central Memory T Cells and HLA-DR\u2009+\u2009Tregs. Cells 12:439. https:\/\/doi.org\/10.3390\/cells12030439","journal-title":"Cells"},{"key":"2597_CR18","doi-asserted-by":"publisher","first-page":"901165","DOI":"10.3389\/fimmu.2022.901165","volume":"13","author":"J Canto-Gomes","year":"2022","unstructured":"Canto-Gomes J, Silva CS, Rb-Silva R et al (2022) Low Memory T Cells Blood Counts and High Na\u00efve Regulatory T Cells Percentage at relapsing remitting multiple sclerosis diagnosis. Front Immunol 13:901165. https:\/\/doi.org\/10.3389\/fimmu.2022.901165","journal-title":"Front Immunol"},{"key":"2597_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/cyto.b.10011","volume":"52B","author":"SS Uppal","year":"2003","unstructured":"Uppal SS, Verma S, Dhot PS (2003) Normal values of CD4 and CD8 lymphocyte subsets in healthy Indian adults and the effects of sex, age, ethnicity, and smoking. Cytometry B Clin Cytom 52B:32\u201336. https:\/\/doi.org\/10.1002\/cyto.b.10011","journal-title":"Cytometry B Clin Cytom"},{"key":"2597_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1046\/j.0902-4441.2003.00199.x","volume":"72","author":"LR Bisset","year":"2004","unstructured":"Bisset LR, Lung TL, Kaelin M et al (2004) Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland. Eur J Haematol 72:203\u2013212. https:\/\/doi.org\/10.1046\/j.0902-4441.2003.00199.x","journal-title":"Eur J Haematol"},{"key":"2597_CR21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.clim.2005.03.020","volume":"116","author":"K Jentsch-Ullrich","year":"2005","unstructured":"Jentsch-Ullrich K, Koenigsmann M, Mohren M, Franke A (2005) Lymphocyte subsets\u2019 reference ranges in an age- and gender-balanced population of 100 healthy adults\u2014A monocentric German study. Clin Immunol 116:192\u2013197. https:\/\/doi.org\/10.1016\/j.clim.2005.03.020","journal-title":"Clin Immunol"},{"key":"2597_CR22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.imbio.2014.02.010","volume":"219","author":"R Valiathan","year":"2014","unstructured":"Valiathan R, Deeb K, Diamante M et al (2014) Reference ranges of lymphocyte subsets in healthy adults and adolescents with special mention of T cell maturation subsets in adults of South Florida. Immunobiology 219:487\u2013496. https:\/\/doi.org\/10.1016\/j.imbio.2014.02.010","journal-title":"Immunobiology"},{"key":"2597_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12865-020-00374-9","volume":"21","author":"H-Q Niu","year":"2020","unstructured":"Niu H-Q, Zhao X-C, Li W et al (2020) Characteristics and reference ranges of CD4\u2009+\u2009T cell subpopulations among healthy adult Han Chinese in Shanxi Province, North China. BMC Immunol 21:44. https:\/\/doi.org\/10.1186\/s12865-020-00374-9","journal-title":"BMC Immunol"},{"key":"2597_CR24","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/cei\/uxab038","volume":"207","author":"Y Xia","year":"2022","unstructured":"Xia Y, Liu A, Li W et al (2022) Reference range of na\u00efve T and T memory lymphocyte subsets in peripheral blood of healthy adult. Clin Exp Immunol 207:208\u2013217. https:\/\/doi.org\/10.1093\/cei\/uxab038","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"2597_CR25","doi-asserted-by":"publisher","first-page":"e0225512","DOI":"10.1371\/journal.pone.0225512","volume":"14","author":"JS Yi","year":"2019","unstructured":"Yi JS, Rosa-Bray M, Staats J et al (2019) Establishment of normative ranges of the healthy human immune system with comprehensive polychromatic flow cytometry profiling. PLoS ONE 14(12):e0225512. https:\/\/doi.org\/10.1371\/journal.pone.0225512","journal-title":"PLoS ONE"},{"key":"2597_CR26","doi-asserted-by":"publisher","first-page":"104179","DOI":"10.1016\/j.ebiom.2022.104179","volume":"82","author":"L Zuroff","year":"2022","unstructured":"Zuroff L, Rezk A, Shinoda K et al (2022) Immune aging in multiple sclerosis is characterized by abnormal CD4 T cell activation and increased frequencies of cytotoxic CD4 T cells with advancing age. EBioMedicine 82:104179. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104179","journal-title":"EBioMedicine"},{"key":"2597_CR27","doi-asserted-by":"publisher","first-page":"819136","DOI":"10.3389\/fimmu.2022.819136","volume":"13","author":"E D\u2019Amico","year":"2022","unstructured":"D\u2019Amico E, Zangh\u00ec A, Parrinello NL et al (2022) Immunological subsets characterization in newly diagnosed relapsing\u2013remitting multiple sclerosis. Front Immunol 13:819136. https:\/\/doi.org\/10.3389\/fimmu.2022.819136","journal-title":"Front Immunol"},{"key":"2597_CR28","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1177\/1352458514536252","volume":"20","author":"MP Pender","year":"2014","unstructured":"Pender MP, Csurhes PA, Pfluger CMM, Burrows SR (2014) Deficiency of CD8\u2009+\u2009effector memory T cells is an early and persistent feature of multiple sclerosis. Multiple Scler J 20:1825\u20131832. https:\/\/doi.org\/10.1177\/1352458514536252","journal-title":"Multiple Scler J"},{"key":"2597_CR29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0022-510X(83)90201-0","volume":"62","author":"J Booss","year":"1983","unstructured":"Booss J, Esiri MM, Tourtellotte WW, Mason DY (1983) Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis. J Neurol Sci 62:219\u2013232. https:\/\/doi.org\/10.1016\/0022-510X(83)90201-0","journal-title":"J Neurol Sci"},{"key":"2597_CR30","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1093\/brain\/123.6.1174","volume":"123","author":"A Bitsch","year":"2000","unstructured":"Bitsch A, Schuchardt J, Bunkowski S et al (2000) Acute axonal injury in multiple sclerosis: correlation with demyelination and inflammation. Brain 123:1174\u20131183. https:\/\/doi.org\/10.1093\/brain\/123.6.1174","journal-title":"Brain"},{"key":"2597_CR31","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1177\/1352458510364992","volume":"16","author":"EC Tallantyre","year":"2010","unstructured":"Tallantyre EC, B\u00f8 L, Al-Rawashdeh O et al (2010) Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Multiple Scler J 16:406\u2013411. https:\/\/doi.org\/10.1177\/1352458510364992","journal-title":"Multiple Scler J"},{"key":"2597_CR32","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.3389\/fimmu.2017.01160","volume":"8","author":"LM Peeters","year":"2017","unstructured":"Peeters LM, Vanheusden M, Somers V et al (2017) Cytotoxic CD4\u2009+\u2009T cells drive multiple sclerosis progression. Front Immunol 8:1160. https:\/\/doi.org\/10.3389\/fimmu.2017.01160","journal-title":"Front Immunol"},{"key":"2597_CR33","doi-asserted-by":"publisher","first-page":"e57820","DOI":"10.1371\/journal.pone.0057820","volume":"8","author":"JR Christensen","year":"2013","unstructured":"Christensen JR, B\u00f6rnsen L, Ratzer R et al (2013) Systemic inflammation in progressive multiple sclerosis involves follicular T-Helper, Th17- and activated B-Cells and correlates with progression. PLoS ONE 8:e57820. https:\/\/doi.org\/10.1371\/journal.pone.0057820","journal-title":"PLoS ONE"},{"key":"2597_CR34","doi-asserted-by":"publisher","first-page":"e951","DOI":"10.1212\/NXI.0000000000000951","volume":"8","author":"M Puthenparampil","year":"2021","unstructured":"Puthenparampil M, Tomas-Ojer P, Hornemann T et al (2021) Altered CSF albumin quotient links peripheral inflammation and brain damage in MS. Neurol Neuroimmunol Neuroinflamm 8:e951. https:\/\/doi.org\/10.1212\/NXI.0000000000000951","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2597_CR35","doi-asserted-by":"publisher","first-page":"219","DOI":"10.4274\/tnd.87523","volume":"23","author":"V Y\u0131lmaz","year":"2017","unstructured":"Y\u0131lmaz V, Tura DA, Ulusoy C et al (2017) Multipl Skleroz hastalar\u0131nda Periferik Kan B lenfosit alt gruplar\u0131n\u0131n ak\u0131m sitometrisi ile de\u011ferlendirilmesi. Turk Noroloji Dergisi 23:219\u2013224. https:\/\/doi.org\/10.4274\/tnd.87523","journal-title":"Turk Noroloji Dergisi"},{"key":"2597_CR36","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1093\/brain\/awh641","volume":"128","author":"A Kutzelnigg","year":"2005","unstructured":"Kutzelnigg A, Lucchinetti CF, Stadelmann C et al (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128:2705\u20132712. https:\/\/doi.org\/10.1093\/brain\/awh641","journal-title":"Brain"},{"key":"2597_CR37","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1212\/WNL.59.4.555","volume":"59","author":"LM Villar","year":"2002","unstructured":"Villar LM, Masjuan J, Gonz\u00e1lez-Porqu\u00e9 P et al (2002) Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 59:555. https:\/\/doi.org\/10.1212\/WNL.59.4.555","journal-title":"Neurology"},{"key":"2597_CR38","doi-asserted-by":"publisher","first-page":"e126599","DOI":"10.1101\/490938","volume":"4","author":"AL Greenfield","year":"2019","unstructured":"Greenfield AL, Dandekar R, Ramesh A et al (2019) Longitudinally persistent cerebrospinal fluid B-cells resist treatment in multiple sclerosis. JCI Insight 4:e126599. https:\/\/doi.org\/10.1101\/490938","journal-title":"JCI Insight"},{"key":"2597_CR39","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1177\/1352458517729455","volume":"23","author":"H Lassmann","year":"2017","unstructured":"Lassmann H (2017) Targets of therapy in progressive MS. Mult Scler 23:1593\u20131599. https:\/\/doi.org\/10.1177\/1352458517729455","journal-title":"Mult Scler"},{"key":"2597_CR40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12883-017-0915-1","volume":"17","author":"H Posov\u00e1","year":"2017","unstructured":"Posov\u00e1 H, Hor\u00e1kov\u00e1 D, \u010capek V et al (2017) Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients. BMC Neurol 17:145. https:\/\/doi.org\/10.1186\/s12883-017-0915-1","journal-title":"BMC Neurol"},{"key":"2597_CR41","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1177\/1352458517748474","volume":"25","author":"J Kroth","year":"2019","unstructured":"Kroth J, Ciolac D, Fleischer V et al (2019) Increased cerebrospinal fluid albumin and immunoglobulin A fractions forecast cortical atrophy and longitudinal functional deterioration in relapsing-remitting multiple sclerosis. Multiple Scler J 25:338\u2013343. https:\/\/doi.org\/10.1177\/1352458517748474","journal-title":"Multiple Scler J"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02597-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-024-02597-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02597-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T02:06:22Z","timestamp":1733277982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-024-02597-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,3]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2597"],"URL":"https:\/\/doi.org\/10.1007\/s13760-024-02597-8","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"type":"print","value":"0300-9009"},{"type":"electronic","value":"2240-2993"}],"subject":[],"published":{"date-parts":[[2024,8,3]]},"assertion":[{"value":"14 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institution\u2019s Ethical Committee (approval No. 8.1\u201323\/69\u2009\u2212\u20092).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"M.H. participated as a clinical investigator and\/or received consultation and\/or speaker fees from: Biogen, Sanofi Genzyme, Merck, Bayer, Novartis, Pliva\/Teva, Roche, Alvogen, Actelion, Alexion Pharmaceuticals, TG Pharmaceuticals. MKS received speaker fees from Sanofi Genzyme and Roche. The other authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}